Citations

Mayo Clinic

Clear

554 citation(s) found for "Oh, Gerald".

Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension
Clinton, Ivor, Coursen, Julie , Rosen, Darin , Suresh, Karthik , Balasubramanian, Aparna , Kolb, Todd M. , Damico, Rachel L. , Mathai, Stephen C. , Hsu, Steven , Mukherjee, Monica , Finet, J. Emanuel , Grünig, Gabriele , Rischard, Franz, Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Group, PVDOMICS Study, Clinton, Ivor W , Coursen, Julie C , Rosen, Darin T , Barnard, John , Hemnes, Anna , Leopold, Jane A , Horn, Evelyn M , Rosenzweig, Erika B , Frantz, Robert P , Erzurum, Serpil C , King, Wendy , Beck, Gerald J , Hill, Nicholas S , Hassoun, Paul M , Simpson, Catherine E , Mathai, Stephen C , Balasubramanian, Aparna , Mukherjee, Monica , Hsu, Steven , Barnard, John , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , King, Wendy C. , Hassoun, Paul M. , Simpson, Catherine E. , Group, PVDOMICS Study

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.732773 | PMID 42395385 Get It

ABSTRACT Background Pulmonary arterial hypertension (PAH) is characterized by circulating metabolic alterations, but whether these reflect disease-specific metabolic programs or reorganization of normal metabolic architecture, and how they relate to right ventricular-pulmonary vascular function (RV-PV), remains unclear. We hypothesized that the PAH metabolome is organized into biologically coherent, co-regulated metabolic modules whose relationships to RV-PV function would provide insight into known and novel metabolic pathways. Methods We applied weighted gene co-expression network analysis (WGCNA) to untargeted metabolomic data from 412 PAH patients enrolled in the multicenter PVDOMICS study. Module preservation analysis was performed in 85 healthy controls, with external replication in an independent single-center pulmonary hypertension cohort of 89 patients. Results WGCNA identified 16 distinct metabolic modules organized around biologically coherent programs. A coherent fatty acid axis, spanning substrate pools, β-oxidation intermediates, and conjugated fatty acid disposal products, formed a central organizing structure, with downstream fatty acid oxidation modules strongly associated with adverse hemodynamics and worse RV-pulmonary artery (PA) coupling. Acylcholine-enriched and 5α-reduced androgen metabolite modules were associated with favorable hemodynamic indices. Module architecture was largely preserved in healthy controls, with subtle disease-associated modular reorganization, rather than emergence of novel modules, observed in PAH. Core modules were recovered in the replication cohort with conserved hub metabolites. Conclusions These findings establish a systems-level framework demonstrating that PAH involves structured intensification and reorganization of interconnected metabolic programs associated with favorable and adverse RV-PV phenotypes. This work provides new insight into the metabolic architecture underlying PAH and identifies coordinated metabolic pathways linked to pulmonary vascular and right ventricular function.
Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICS
Rischard, Franz , Mendoza, Mateo, Insel, M, Beck, Gerald J. , Erzurum, Serpil C. , Frantz, Robert P. , Finet, J. Emanuel , Hassoun, Paul M. , Hemnes, Anna R. , Hill, Nicholas S. , Group, the PVDOMICS Study, Rischard, Franz P , Horn, Evelyn M , Leopold, Jane A , Mathai, Stephen C , Mehra, Reena , Nishimura, Rick , Rosenzweig, Erika B , Systrom, David M , Tang, W H Wilson , Waxman, Aaron B. , Borlaug, Barry A , Frantz, Robert P , Hemnes, Anna , Hassoun, Paul M , Beck, Gerald J , Finet, J Emanuel , Mendoza, Mateo, Insel, Michael , Horn, Evelyn M. , Leopold, Jane A. , Mathai, Stephen C. , Mehra, Reena , Reddy, Yogesh N.V. , Rosenzweig, Erika B. , Tang, W.H. Wilson , Borlaug, Barry A. , Group, The PVDOMICS Study

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.04.26354961 | PMID 42326784 Get It

Abstract Background World Symposium on Pulmonary Hypertension (WSPH) Group 2 pulmonary hypertension (PH) is a clinically integrated phenotype attributed to left heart disease, whereas pre- versus post-capillary classification is operationalized primarily by pulmonary capillary wedge pressure (PCWP). Although current recommendations emphasize contextual interpretation and provocative testing for intermediate PCWP values, the relationship between PCWP-based classification and underlying phenotype has not been systematically evaluated. We aim to quantify phenotype–hemodynamic discordance across the PCWP spectrum and evaluate a staged physiology-guided framework incorporating inhaled nitric oxide (iNO), ventricular geometry, and provocative testing. Methods We studied 1,032 participants from the NHLBI-sponsored PVDOMICS cohort with multidisciplinary adjudicated phenotypes integrating clinical, imaging, physiologic, and hemodynamic data. Stage-specific PCWP thresholds classified pre- versus post-capillary physiology at rest, during iNO, and during provocation (fluid challenge or invasive cardiopulmonary exercise testing [iCPET]). Echocardiographic right ventricular-to-left ventricular (RV/LV) ratio was evaluated as a marker of ventricular interdependence. Restricted cubic spline and staged concordance analyses defined certainty-based PCWP ranges and incremental diagnostic yield. Results Adjudicated Group 2 PH was present in 37.0% of participants. Resting PCWP demonstrated good discrimination (AUC 0.86), but substantial bidirectional phenotype–hemodynamic discordance persisted across intermediate PCWP ranges. At a resting PCWP of 12 mmHg, 25% of participants classified as pre-capillary had adjudicated Group 2 PH, whereas at 18 mmHg, 35% classified as post-capillary remained discordant non–Group 2. Concordance did not approach 90% until PCWP values were <9 mmHg or >24 mmHg. Dynamic testing incrementally improved concordance within these overlap zones. Nearly half of adjudicated Group 2 PH participants (46.5%) were not identified by resting PCWP alone; incorporation of iNO and provocative testing increased cumulative Group 2 identification by 63.4% and improved sensitivity from 79.9% to 83.7%. Model discrimination improved from an AUC of 0.863 to 0.908 (likelihood-ratio P<0.001). iNO increased PCWP in discordant Pre/G2 participants, unmasking latent left-sided limitation, while lowering PCWP in discordant Post/NonG2 participants, consistent with ventricular interdependence. RV/LV ratio ≥0.94 reduced discordant Post/NonG2 classification by 70.5%, and incorporation of PCWP/cardiac output slope improved physiologic specificity during exercise. Conclusions Group 2 PH is a dynamic, load-dependent phenotype inadequately characterized by resting PCWP alone. Intermediate PCWP values represent continuous probabilities of bidirectional discordance rather than discrete diagnostic states. A staged physiology-guided approach integrating iNO, ventricular geometry, and provocative testing improves concordance between hemodynamic classification and clinically integrated phenotype assignment. Clinical Perspective What Is New? In the deeply phenotyped PVDOMICS cohort, resting pulmonary capillary wedge pressure demonstrated good overall discrimination for adjudicated Group 2 (left heart disease) pulmonary hypertension, yet intermediate values frequently either concealed latent left-heart disease or overclassified patients without intrinsic left-heart disease Resting pulmonary capillary wedge pressure should be viewed as a continuous probability signal rather than a binary threshold, allowing additional physiologic testing to be targeted according to the degree of diagnostic uncertainty a clinician is willing to accept. A staged physiology-guided approach incorporating inhaled nitric oxide, ventricular geometry, and provocative testing improved concordance with adjudicated PH category and pre or post-capillary classification. What Are the Clinical Implications? Pre- versus post-capillary classification should be interpreted within the broader clinical and physiologic context rather than relying on a single resting pulmonary capillary wedge pressure threshold. Intermediate pulmonary capillary wedge pressure values should prompt consideration of additional physiologic evaluation, with inhaled nitric oxide providing a practical intermediate step and provocative testing providing the greatest incremental diagnostic yield. Exercise pulmonary capillary wedge pressure/cardiac output slope and markers of ventricular interdependence may provide complementary information for resolving uncertainty when resting and dynamic hemodynamics are discordant.
Long-term eculizumab treatment failure in C3 glomerulonephritis: two case reports
Soler, María José , Cara, Anila, Sethi, Sanjeev , Appel, Gerald B, Santoriello, Dominick , Santos, Fernanda Dos, Fervenza, Fernando C. , Zubidat, Dalia , Soler, Maria Jose , Cara, Anila , Sethi, Sanjeev , Dos Santos, Fernanda G, Fervenza, Fernando C , Appel, Gerald B.

Clinical Kidney Journal | June 9, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1093/ckj/sfag189 | PMID 42415834 Get It

ABSTRACT C3 glomerulonephritis (C3GN) is a rare kidney disease driven by dysregulation of the alternative complement pathway. We report two challenging cases of patients with C3GN in whom various immunosuppressant therapies have failed to achieve complete remission, prompting treatment with eculizumab, an anti-C5 humanized monoclonal antibody that inhibits the terminal complement pathway. Although transient improvement in kidney function was observed, both patients eventually experienced worsening renal parameters, with increasing proteinuria and hematuria, culminating in progression to end-stage kidney disease. Repeated kidney biopsies following eculizumab therapy demonstrated persistent, granular mesangial and capillary wall C3 (3+) staining on immunofluorescence studies, indicating ongoing complement activation upstream of the C5 blockade and the perpetuation of C3 deposits in the glomeruli. These cases underscore the limited efficacy of terminal complement inhibition in halting disease progression in C3GN.
Implementing the 3-Day Skilled Nursing Facility Waiver: Key Insights
Newman, James S. , Johnson, Kristin S., Meyer, Tia J., ANDERSON, VICTORIA L., Baumbach, Lori J., Tjornhom, Amy R. Hunt, Lexvold, Leanne Y., Manz, James W., Sobolik, Gerald J. , Madden, Kathleen A., Hunt Tjornhom, Amy R, Manz, James W., Madden, Kathleen A.

Journal of Primary Care & Community Health | May 30, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261456960 | PMID 42217227 Get It

Introduction The Centers for Medicare & Medicaid skilled nursing facility (SNF) 3-day waiver permits patients attributed to an Accountable Care Organization (ACO) to be admitted to an SNF or transitional care unit from an emergency department, outpatient setting, inpatient stay (<3 days), or observational status without Medicare’s requisite 3-day inpatient stay. Methods Our institution’s ACO implemented the waiver program in 2023. We report our experience with implementing the waiver and describe benefits and barriers, as well as interventions developed, outcomes achieved, and opportunities presented for patients and health care facilities. Results Through a streamlined process, patients can more readily access essential care, and health care facilities benefit from enhanced efficiency. Furthermore, the ACO can more effectively manage health care utilization and cost. Although the program offers benefits to patients, their families, and health care facilities, implementing and maintaining the program has challenges, with barriers including underdeveloped workflows, gaps in staff education and communication, difficulties in patient identification, and challenges with specific facility requirements. Conclusions The SNF 3-day rule waiver has been valuable in enhancing patient care and optimizing health care delivery within our ACO. Ongoing efforts to refine processes and address challenges will further improve the program’s effectiveness and sustainability.
Applying learning science principles (LSP) in a workshop (WS) for hematology and oncology (HemOnc) trainees (HOT) about how to use artificial intelligence (AI) in medical education (MedEd) and clinical practice (CP).
Correia, Guilherme Sacchi de Camargo, Ghani, Nabil , Terrell, Christopher, Schofield, Ashley Danielle, Aleksan, Mina, Dalgetty, Mark, Iska, Sindu , Leurinda, Christian, Akpan, Inemesit , Herrington, Kyler, Hickman, Lyle J., Shah, Anvay , Peters, Daniel Thomas, Dainer, Paul M., Wallace, Gerald , Raval, Girindra , Dalgetty, Mark, Hickman, Lyle J., Dainer, Paul , Keruakous, Amany R. , Manochakian, Rami

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9030-9030

10.1200/jco.2026.44.16_suppl.9030 Get It

9030 Background: AI use is ubiquitous among HOT and healthcare workers, but with variable base knowledge and comfort level. Its indiscriminate use may be problematic. To address this educational gap, we developed a WS for HOT to assess their use of AI and educate them on how to employ it in MedEd and patient-centered CP based on LSP. Methods: A faculty member developed a WS on how to use AI in MedEd and CP based on LSP of analogy, contrasting cases, elaboration, generation, and question driven learning. The WS was for HOT, but faculty could join. It had 3 sections: introduction to basic concepts of AI; principles of the Health Insurance Portability and Accountability Act and protected health information; AI in MedEd; and AI in CP. Sections had real use case examples of AI, for participants to interact, ask questions, and share their personal use cases. HOT were invited to compare and generate examples during the WS, based on their educational and clinical experience and needs. Participants’ AI use and self-perceived and objective knowledge about it were assessed in a pre activity survey, a post WS survey, and a post 8 week survey to evaluate long term learning. Results: A 2 hour WS with 9 HOT and 2 faculty was completed successfully. 10 participants completed the pre WS survey, and 11 completed the post WS and the post 8 week surveys. 100% of them used generative AI tools before the WS, while 10% had prior training in AI. 90% used AI in personal life and MedEd, 70% used it in CP, and 30% in academic research. Table 1 shows participants’ self-assessed knowledge of AI, comfort level in using AI for MedEd and CP, self-assessed preparedness to implement AI in MedEd and CP, and objective knowledge. 8 weeks post WS, 91% of participants reported increased AI use in CP, leading anywhere from slight to significant decreases in time spent on documentation tasks for 91% of them. In MedEd, 73% reported increased AI use, and 82% described slight to significant improvement in the quality of time dedicated to it. 82% described the WS as extremely relevant to their daily responsibilities, and 91% reported confidence navigating ethical and privacy risks of AI in HemOnc. All participants were interested in having a similar WS in the future. Conclusions: An LSP based WS about AI increased the self-perceived and objective knowledge of HOT about using this tool in MedEd and CP. It also increased HOT comfort level, preparedness, and efficiency using AI. With the ubiquitous use of AI by HOT, ongoing education about it focused on supporting high-quality patient care should be a part of fellowship curriculum. Pre WS % Post WS % Post 8 week % Moderately/Very knowledgeable about AI 50 91 100 Comfortable using AI in MedEd 60 82 82 Prepared to implement AI in MedEd 30 91 73 Comfortable using AI in CP 40 73 82 Prepared to implement AI in CP 0 91 73 Correct answers on objective assessment 53 68 71
Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer
Konecny, Gottfried, Cohen, Joshua, Colón‐Otero, Gerardo , Danziger, Natalie , Lin, Douglas I. , Li, Gerald , Quintanilha, Julia C.F., Decker, Brennan , Ross, Jeffrey S. , Gearing, Mary, Baker, Kathryn, Scott, Takara, Poyser, Lynette, Vallejos, Paul , Elvin, Julia A. , Cohen, Joshua G. , Konecny, Gottfried E , Cohen, Joshua , Colon-Otero, Gerardo , Danziger, Natalie , Lin, Douglas I , Li, Gerald , Decker, Brennan , Ross, Jeffrey S , Vallejos, Paul , Elvin, Julia A , Graf, Ryon P , Swisher, Elizabeth M. , Quintanilha, Júlia C.F. , Gearing, Mary E., Scott, Takara A., Graf, Ryon P.

JCO Precision Oncology | May 14, 2026 | Volume: 10 | Issue: 5 | Pages: No page available

10.1200/po-25-00763 | PMID 42133897 Get It

PURPOSE We sought to characterize outcome associations of poly ADP-ribose polymerase inhibitors (PARPi) in patients with ovarian cancer (OVCA) whose cancers contain homozygous loss (deletions) of homologous recombination repair (HRR) pathway genes, an alteration class not uniformly reported on clinical testing and not susceptible to acquired resistance via secondary reversion mutations. METHODS This study used US-based deidentified Flatiron Health-Foundation Medicine OVCA Clinico-Genomic Database. Patients with advanced OVCA and genomic profiling by Foundation Medicine were assembled into cohorts evaluating PARPi monotherapy use, and separately, PARPi maintenance therapy use, with outcomes associated with HRR gene alterations: BRCA1 / 2 , PALB2 , RAD51B/C/D , BARD1 , and BRIP1 . RESULTS 1.5% (82/5,404) had HRR gene homozygous loss, with BRCA1 and BRCA2 loss being most common. Among all OVCAs with BRCA1/2 alterations, 7.5% (63/836) were homozygous losses. Most BRCA1 (34/38, 89%) and BRCA2 (18/25, 72%) homozygous losses were intragenic, with breakpoints not spanning entire gene. Maintenance cohort: 22 patients had HRR gene homozygous loss, with strongly improved progression-free survival (PFS) for PARPi versus no PARPi use (HR, 0.06, 95% CI, 0.01 to 0.37). Monotherapy cohort: patients without HRR alterations (n = 198), HRR mutations or rearrangements (n = 93), and HRR homozygous loss (n = 8) had median PFS of 4.9, 10.6, and 25.4 months, and median overall survival of 18.5, 22.5, and 51.8 months, respectively. CONCLUSION We observe durable PARPi effectiveness for patients with OVCA and HRR gene homozygous loss in routine practice. We demonstrate the importance of detecting and reporting homozygous loss in HRR genes, an aspect not standard to all sequencing assays.
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Cohen, Stuart H. , Allyn, Paul , Rathe, Jennifer , Nanayakkara, Deepa , Hutfles, Gerald, Vijayan, Tara , Smith, Ethan A , Saling, Christopher , Ilges, Dan , Schlamm, Haran T., Thompson, George R. , Rathe, Jennifer , Hutfles, Gerald , Vijayan, Tara , Smith, Ethan A , Ilges, Dan , Thompson, George R , Allyn, Paul R , Chow, Felicia C.

Clinical Infectious Diseases | April 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag271 | PMID 42015519 Get It

Abstract Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix (“gepix”), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; nonmeningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.
Metabolomics of Right Ventricular Function in Pulmonary Hypertension
Chacon-Barahona, Jonathan , Chung, Samuel J. , Garry, Jonah , Frantz, Robert P. , Hassoun, Paul M. , Mathai, Stephen C. , Simpson, Catherine E. , Beck, Gerald, Hill, Nicholas S. , MUKHERJEE, MONICA, Jacob, Miriam , Park, M H, Finet, J Emanuel, Farha, Samar , Grünig, Gabriele , Kwon, Deborah, Comhair, Suzy , Erzurum, Serpil, Barnard, John, Jellis, Christine , Racanelli, Alexandra Christin, Krumsiek, Jan , hemnes, anna, Horn, Evelyn, Group, on behalf of the PVDOMICS Study, Beck, Gerald J. , Garry, Jonah D , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Beck, Gerald J , Hill, Nicholas S , Leopold, Jane A , Waxman, Aaron B. , Rosenzweig, Erika B , Borlaug, Barry A , Mukherjee, Monica , Vanderpool, Rebecca R , Jacob, Miriam , Mehra, Reena , Park, Margaret M , Finet, J Emanuel , Kwon, Deborah H , Comhair, Suzy , Erzurum, Serpil C , Barnard, John , Hu, Bo , Jellis, Christine L , Krumsiek, Jan , Brittain, Evan L , Hemnes, Anna , Horn, Evelyn M , Frantz, Robert P , Chacon-Barahona, Jonathan , Chung, Samuel J. , Rischard, Franz , Leopold, Jane A. , Rosenzweig, Erika B. , Borlaug, Barry A. , Mukherjee, Monica , Vanderpool, Rebecca , Mehra, Reena , Finet, J. Emanuel , Erzurum, Serpil C. , Racanelli, Alexandra C. , Hemnes, Anna R. , Gro, on behalf of the PVDOMICS Study

Circulation Research | April 15, 2026 | Volume: 138 | Issue: 11 | Pages: No page available

10.1161/circresaha.125.327342 | PMID 41983297 Get It

BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.
Social Risk Factors and Their Effect on Health Care Costs in a Midwestern Health Care System
Bernard, Matthew E., Sosso, Jessica , Jegen, Dominika , Allen, Summer V. , Fischer, Karen M., Sobolik, Gerald J. , Dickes, Jadyn R., Foss, Randy , Maxson, Julie, Garrison, Gregory M. , Bernard, Matthew , Bernard, Matthew E , Sosso, Jessica L , Jegen, Dominika A , Foss, Randy , Maxson, Julie A, Lampman, Michelle A. , Thacher, Thomas D , Fischer, Karen M. , Thacher, Tom D.

Journal of Primary Care & Community Health | March 31, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261431146 | PMID 41914552 Get It

Objectives: To assess how social risk factors and socioeconomic status (SES) affect health care costs at a large, integrated health system of 45 clinics in Iowa, Minnesota, and Wisconsin. Methods: We retrospectively reviewed administrative patient cost data from January 1 through December 31, 2022. Social risk factors (lack of financial resources, food insecurity, intimate partner violence, unmet transportation needs, and housing instability) were determined with patient questionnaires. Cost z -scores were compared across all risk-factor quartiles. We used a housing-based measure to objectively determine SES. Results: We analyzed data from 410 624 patients empaneled with 689 family medicine clinicians. Self-reported risk factor data were incomplete for 219 321 patients. Costs were higher for those with higher social risk (mean cost z -score: high risk = 0.38, low risk = 0.11; P < .001). In addition, higher costs were associated with increasing age, greater medical complexity (higher Adjusted Clinical Group scores), White race, and lack of financial resources. Although we observed geographic variations in cost, urban and rural locations did not have significant cost differences. Costs were similar across all quartiles of SES, and the absolute difference in cost z -scores between the highest and lowest SES quartiles was only 0.04. The multivariate analysis, which adjusted for age, medical complexity, race, sex, and objective SES, showed that these specific associations were substantially decreased and no longer significantly associated with mean cost z -scores. Conclusions: Patient-reported social risk factors were significantly associated with increased cost of care in a large, multispecialty health system in the midwestern US. These associations were decreased in the multivariate analysis. Results should be interpreted cautiously for readers outside the midwestern US, given potential responder bias and the racial homogeneity (92% White) of the study cohort.